Compassionate Use of Omegaven to Reverse Parenteral Nutrition Induced Cholestasis

Cholestasis Clinical Trial

Official title:

Compassionate Use of a Fish Oil-derived Intravenous Fat Emulsion (Omegaven) to Reverse Parenteral Nutrition (PN) Induced Cholestasis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01173159
• Other study ID #: 2009-2314
• Status: Completed
• Phase: N/A
• Start date: July 2010
• Est. completion date: December 2018

Study information

• Verified date: June 2020
• Source: Children's Hospital Medical Center, Cincinnati
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this research study is to see if giving Omegaven (an intravenous fat emulsion containing fish oil) instead of the current lipid emulsion, which contains fat derived from soybeans, as part of your child's intravenous (IV) nutrition therapy may be tolerated better. It may reduce the harmful effects to the liver, may stop any further liver damage and may reverse damage already done to the liver because of the prolonged use of nutrition through your child's IV.

Description:

Enrollment of subjects into this study will occur for up to 4 years. Subjects will receive Omegaven at a dose of up to 1 g/kg body weight/day until they no longer require total parenteral nutrition or until their conjugated/direct bilirubin has normalized and their enteral lipid intake is sufficient to discontinue intravenous lipids.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: December 2018
• Est. primary completion date: December 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Month to 18 Years

Eligibility

Inclusion Criteria:

• Males and females ages one month of age to 18 years of age

• Patients with intestinal failure on TPN

• Patients who have a conjugated/direct bilirubin of =3 mg/dl for more than weeks and in whom other causes of cholestasis have been excluded with reasonable certainty utilizing biochemical, serologic, microbiologic, and radiographic techniques. Liver biopsy is not required to rule out other disorders, but may be utilized at the clinician's discretion

• Patients in whom reduction of IV soy-based lipid to an average <1.2g/kg body weight/day has failed to reduce the conjugated/direct bilirubin within = 30 days of implementation

• Willing to use birth control during study participation for females of child- bearing potential, as determined by investigator.

• Signed informed consent for use of Omegaven® obtained

Exclusion Criteria:

• Any of the contraindications to use of Omegaven®

• Impaired lipid metabolism (triglycerides >1000 mg/dL) while on

1g/kg/day or less of Intralipid

• History of severe hemorrhagic disorders (ie. hemophilia, Von Willebrand disease, etc.)

• Unstable diabetes mellitus

• Collapse and shock

• Stroke/ Embolism

• Cardiac infarction within the last 3 months

• Undefined coma status

• Pregnancy (positive pregnancy test) prior to enrollment in the study for females of child-bearing potential

• Females of child-bearing potential who are unwilling to use birth control during study participation

• Parental decision to forego the use of Omegaven®

• Known fish or egg allergy

• Pregnancy

• Causes of liver disease other than Parenteral Nutrition Associated Cholestasis

Related Conditions & MeSH terms

• Cholestasis

Intervention

Drug:
• Omegaven
For the first two days of treatment, subjects will receive Omegaven® at 0.5 g/kg per day to assess tolerance and will progress to a maintenance dosage of up to 1g/kg per day over 12 hours at an infusion rate of 1 g/kg/12 hours (10 ml/kg/12 hours). Dosing is based on previously described dosing of fish-oil emulsions as monotherapy noted within the literature. Omegaven® will be infused intravenously through either a central or peripheral catheter in conjunction with other parenteral nutrition containing dextrose and amino acids. Omegaven® is isotonic. It is compatible with parenteral nutrition solutions and may be co-infused via y-site.

Locations

Country	Name	City	State
United States	Cincinnati Children's Hospital Medical Center	Cincinnati	Ohio

Sponsors (1)

Lead Sponsor	Collaborator
Children's Hospital Medical Center, Cincinnati

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With a Change in Conjugated/Direct Bilirubin	Change in conjugated/direct bilirubin level to below 1 mg/dl.	Completion of Therapy (time frame from 1-14 weeks)
Secondary	Number of Participants With a Change in Unconjugated/Total Bilirubin	Change in unconjugated/total bilirubin level to below 1.1 mg/dL. General outcomes of participants are reported due to the enrollment of very few patients so that we have too small a cohort with which to assess achievement of our stipulated outcomes.	Completion of Therapy (time frame from 1-14 weeks)
Secondary	Number of Participants With a Change in Aspartate Transaminase (AST)	Change in aspartate transaminase (AST) 57 units/L. General outcomes of participants are reported due to the enrollment of very few patients so that we have too small a cohort with which to assess achievement of our stipulated outcomes.	Completion of Therapy (time frame from 1-14 weeks)
Secondary	Number of Participants With a Change in Liver Enzyme (ALT)	Change in liver enzyme ALT to below 59 unit/L. General outcomes of participants are reported due to the enrollment of very few patients so that we have too small a cohort with which to assess achievement of our stipulated outcomes.	Completion of Therapy (time frame from 1-14 weeks)
Secondary	Number of Participants With a Change in Liver Enzyme Alkaline Phosphatase	Change in liver enzyme alkaline phosphatase to below 345 unit/L. General outcomes of participants are reported due to the enrollment of very few patients so that we have too small a cohort with which to assess achievement of our stipulated outcomes.	Completion of Therapy (time frame from 1-14 weeks)
Secondary	Number of Participants With a Change in Liver Enzyme Gamma-glutamyltransferase (GGT)	Change in Liver Enzyme Gamma-glutamyltransferase (GGT) to below 15 unit/L. General outcomes of participants are reported due to the enrollment of very few patients so that we have too small a cohort with which to assess achievement of our stipulated outcomes.	Completion of Therapy (time frame from 1-14 weeks)
Secondary	Number of Participants With a Change in Triglycerides	Change in Triglycerides to below 119 mg/dL. General outcomes of participants are reported due to the enrollment of very few patients so that we have too small a cohort with which to assess achievement of our stipulated outcomes.	Completion of Therapy (time frame from 1-14 weeks)